5-(2,3-Dihydro-indole-1-sulfonyl)-1,3-dihydro-indol-2-one | 358732-89-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 5-(2,3-Dihydro-indole-1-sulfonyl)-1,3-dihydro-indol-2-one
• 英文别名: 5-(2,3-dihydro-indole-1-sulfonyl)-2-oxo-1,2-dihydro-indole；5-(2,3-dihydroindol-1-ylsulfonyl)-1,3-dihydroindol-2-one
• CAS: 358732-89-5
• 化学式: C₁₆H₁₄N₂O₃S
• mdl: MFCD08248513
• 分子量: 314.365
• InChiKey: KRXINRJZGKMNHE-UHFFFAOYSA-N

物化性质

• 密度：
  1.438±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  22
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  74.9
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  5-(2,3-Dihydro-indole-1-sulfonyl)-1,3-dihydro-indol-2-one 、 2-formyl-5-(2-pyrrolidine-1-yl-ethoxy)-1H-indole 生成 5-(2,3-Dihydro-indole-1-sulfonyl)-3-[5-(2-pyrrolidin-1-yl-ethoxy)-1H-indol-2-ylmethylene]-1,3-dihydro-indol-2-one
  参考文献：
  名称：

  Indolinone derivatives as protein kinase/phosphatase inhibitors

  摘要：

  本发明涉及某些2-吲哚酮化合物，其调节蛋白激酶（“PKs”）和磷酸酶的活性。因此，本发明的化合物在治疗与异常PK活性相关的疾病方面有用。还公开了包含这些化合物的制药组合物、利用包含这些化合物的制药组合物治疗疾病的方法以及制备它们的方法。

  公开号：

  US20020052369A1
• 作为产物：
  描述：

  吲哚啉 、 2-氧代吲哚啉-5-磺酰氯 在 吡啶 作用下， 以 四氢呋喃 为溶剂， 反应 24.0h， 生成 5-(2,3-Dihydro-indole-1-sulfonyl)-1,3-dihydro-indol-2-one
  参考文献：
  名称：

  Sulfonamide substituted indolinones as inhibitors of DNA dependent protein kinase (DNA-PK)

  摘要：

  本发明通常涉及放射增敏剂领域，这些放射增敏剂能够通过抑制DNA-PK（DNA-蛋白激酶）来增强放射疗法。具体而言，涉及抑制DNA-PK的磺胺基取代吲哚酮。

  公开号：

  US20040266843A1

文献信息

• Sulfonamide substituted indolinones as inhibitors of DNA dependent protein kinase (DNA-PK)
  申请人：Sugen, Inc.

  公开号：US20040266843A1

  公开（公告）日：2004-12-30

  The present invention relates generally to the field of radiosensitizing agents which are capable of enhancing radiotherapy by inhibiting DNA-PK (DNA-protein kinase). In particular, it relates to sulfonamide substituted indolinones which inhibit DNA-PK.

  本发明通常涉及放射增敏剂领域，这些放射增敏剂能够通过抑制DNA-PK（DNA-蛋白激酶）来增强放射疗法。具体而言，涉及抑制DNA-PK的磺胺基取代吲哚酮。
• 3-(pyrolyllactone)-2-indolinone compounds as kinase inhibitors
  申请人：——

  公开号：US20020042427A1

  公开（公告）日：2002-04-11

  The invention relates to certain indolinone compounds, their method of synthesis, and a combinatorial library consisting of the indolinone compounds of the invention. The invention also relates to methods of modulating the function of protein kinases using indolinone compounds of the invention and methods of treating diseases by modulating the function of protein kinases and related signal transduction pathways.

  该发明涉及某些吲哚酮化合物，它们的合成方法，以及由该发明的吲哚酮化合物组成的组合库。该发明还涉及使用该发明的吲哚酮化合物调节蛋白激酶功能的方法，以及通过调节蛋白激酶功能和相关信号传导途径治疗疾病的方法。
• Discovery of Pyrrole−Indoline-2-ones as Aurora Kinase Inhibitors with a Different Inhibition Profile
  作者：Chao-Cheng Chiang、Yu-Hsiang Lin、Shu Fu Lin、Chun-Liang Lai、Chiawei Liu、Win-Yin Wei、Sheng-chuan Yang、Ru-Wen Wang、Li-Wei Teng、Shih-Hsien Chuang、Jia-Ming Chang、Ta-Tung Yuan、Ying-Shuen Lee、Paonien Chen、Wei-Kuang Chi、Ju-Ying Yang、Hung-Jyun Huang、Chu-Bin Liao、Jiann-Jyh Huang

  DOI：10.1021/jm1001869

  日期：2010.8.26

  A series of pyrrole-indolin-2-ones were synthesized, and their inhibition profile for Aurora kinases was studied. The potent compound 33 with phenylsulfonamido at the C-5 position and a carboxyethyl group at the C-3' position selectively inhibited Aurora A over Aurora B with IC(50) values of 12 and 156 nM, respectively. Replacement of the carboxyl group with an amino group led to compound 47, which retained the activity for Aurora B and lost activity for Aurora A (IC(50) = 2.19 mu M). Computation modeling was used to address the different inhibition profiles of 33 and 47. Compounds 47 and 36 (the ethyl ester analogue of 33) inhibited the proliferation of HCT-116 and HT-29 cells and suppressed levels of the phosphorylated substrates of Aurora A and Aurora B in the Western blots.
• 3-(PYROLYLLACTONE)-2-INDOLINONE COMPOUNDS AS KINASE INHIBITORS
  申请人：Sugen, Inc.

  公开号：EP1259514A2

  公开（公告）日：2002-11-27
• INDOLINONE DERIVATIVES AS PROTEIN KINASE/PHOSPHATASE INHIBITORS
  申请人：Sugen, Inc.

  公开号：EP1294688A2

  公开（公告）日：2003-03-26